Jim Beach
Chief Operating Officer at Camargo Pharmaceutical Services LLC
Jim Beach active positions
| Companies | Position | Start | End |
|---|---|---|---|
Camargo Pharmaceutical Services LLC
 Camargo Pharmaceutical Services LLC Miscellaneous Commercial ServicesCommercial Services Camargo Pharmaceutical Services LLC provides contract drug development, formulation, testing and regulatory consulting services. The company was founded by Kenneth V. Phelps and Ruth E. Stevens in 2003 and is headquartered in Cincinnati, OH. | Chief Operating Officer | 19/11/2013 | - |
Bexion Pharmaceuticals, Inc.
 Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Chief Operating Officer | - | - |
Career history of Jim Beach
Statistics
International
| United States | 3 |
Operational
| Chief Operating Officer | 2 |
Sectoral
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Camargo Pharmaceutical Services LLC
Camargo Pharmaceutical Services LLC Miscellaneous Commercial ServicesCommercial Services Camargo Pharmaceutical Services LLC provides contract drug development, formulation, testing and regulatory consulting services. The company was founded by Kenneth V. Phelps and Ruth E. Stevens in 2003 and is headquartered in Cincinnati, OH. | Commercial Services |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Commercial Services |
- Stock Market
- Insiders
- Jim Beach
- Experience